Patients with CAA had lower levels of p‐tau 217 than the AD group (0.69 ± 0.76 pg/mL vs. 1.28 ± 0.97 pg/mL, p < 0.001, Figure 2A). This evidence concerns the gene MAPT and Alzheimer disease.